Meta-analysis of the literature on diagnostic accuracy of SPECT in parkinsonian syndromes

BMC Neurology

Volumn 7, Issue , 2007, Pages

  Vlaar, Annemarie M M ^a   van Kroonenburgh, Marinus J P G ^a   Kessels, Alfons G H ^a   Weber, Wim E J ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

[2 [[2 [[[3 (4 CHLOROPHENYL) 8 METHYL 8 AZABICYCLO[3.2.1]OCT 2 YL]METHYL](2 MERCAPTOETHYL)AMINO]ETHYL]AMINO]ETHANETHIOLATO]OXOTECHNETIUM TC 99M; DOPAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; TRACER; DIAGNOSTIC AGENT;

ARTICLE; CLINICAL EXAMINATION; CLINICAL TRIAL; COCHRANE LIBRARY; DATA ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DOPAMINERGIC SYSTEM; EMBASE; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; FOLLOW UP; GOLD STANDARD; HUMAN; MEDICAL LITERATURE; MEDLINE; META ANALYSIS; METHODOLOGY; PARKINSON DISEASE; PARKINSONISM; POSTSYNAPTIC MEMBRANE; PRESYNAPTIC NERVE; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SYSTEMATIC REVIEW; BRAIN; NERVE TRACT; PATHOPHYSIOLOGY; PHYSIOLOGY; PREDICTION AND FORECASTING; REPRODUCIBILITY; RISK; SCINTISCANNING; STANDARD; SYNAPTIC TRANSMISSION;

BRAIN; DIAGNOSIS, DIFFERENTIAL; DOPAMINE AGENTS; HUMANS; NEURAL PATHWAYS; ODDS RATIO; PARKINSONIAN DISORDERS; PREDICTIVE VALUE OF TESTS; REPRODUCIBILITY OF RESULTS; SYNAPTIC TRANSMISSION; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 35948961138     PISSN: None     EISSN: 14712377     Source Type: Journal    
DOI: 10.1186/1471-2377-7-27     Document Type: Article

References (84)

1. Elbaz A Bower JH Maraganore DM McDonnell SK Peterson BJ Ahlskog JE Schaid DJ Rocca WA Risk tables for parkinsonism and Parkinson's disease J Clin Epidemiol 2002, 55:25-31 10.1016/S0895-4356(01)00425-5 11781119
2. Hughes AJ Daniel SE Kilford L Lees AJ Accuracy of clinical diagnosis of idiopathic Parkinson's disease: A clinico-pathological study of 100 cases J Neurol Neurosurg Psychiatry 1992, 55:181-184 1564476
3. Koller WC Montgomery EB Issues in the early diagnosis of Parkinson's disease Neurology 1997, 49:S10-25 9222271
4. Hughes AJ Daniel SE Blankson S Lees AJ A clinicopathologic study of 100 cases of Parkinson's disease Arch Neurol 1993, 50:140-148 8431132
5. Hughes AJ Daniel SE Lees AJ Improved accuracy of clinical diagnosis of Lewy body Parkinson's disease Neurology 2001, 57:1497-1499 11673599
6. Rajput AH Rozdilsky B Rajput A Accuracy of clinical diagnosis in parkinsonism - a prospective study Can J Neurol Sci 1991, 18:275-278 1913360
7. Watanabe H Saito Y Terao S Ando T Kachi T Mukai E Aiba I Abe Y Tamakoshi A Doyu M Hirayama M Sobue G Progression and prognosis in multiple system atrophy: An analysis of 230 Japanese patients Brain 2002, 125:1070-1083 10.1093/brain/awf117 11960896
8. Litvan I MacIntyre A Goetz CG Wenning GK Jellinger K Verny M Bartko JJ Jankovic J McKee A Brandel JP Chaudhuri KR Lai EC D'Olhaberriague L Pearce RK Agid Y Accuracy of the clinical diagnoses of Lewy body disease, Parkinson disease, and dementia with Lewy bodies: A clinicopathologic study Arch Neurol 1998, 55:969-978 10.1001/ archneur.55.7.969 9678315
9. Piccini P Whone A Functional brain imaging in the differential diagnosis of Parkinson's disease Lancet Neurol 2004, 3:284-290 10.1016/ S1474-4422(04)00736-7 15099543
10. Clarke CE Neuroprotection and pharmacotherapy for motor symptoms in Parkinson's disease Lancet Neurol 2004, 3:466-474 10.1016/ S1474-4422(04)00823-3 15261607
11. Dujardin K Defebvre L Duhamel A Lecouffe P Rogelet P Steinling M Destee A Cognitive and SPECT characteristics predict progression of Parkinson's disease in newly diagnosed patients J Neurol 2004, 251:1383-1392 10.1007/ s00415-004-0549-2 15592735
12. Ponsen MM Stoffers D Booij J van Eck-Smit BLF Wolters EC Berendse HW Idiopathic hyposmia as a preclinical sign of Parkinson's disease Ann Neurol 2004, 56:173-181 10.1002/ana.20160 15293269
13. Storch A Hofer A Kruger R Schulz JB Winkler J Gerlach M New developments in diagnosis and treatment of Parkinson's disease - from basic science to clinical applications J Neurol 2004, 251 Suppl 6: VI/33 8
14. Walter U Klein C Hilker R Benecke R Pramstaller PP Dressler D Brain parenchyma sonography detects preclinical parkinsonism Mov Disord 2004, 19:1445-1449 10.1002/mds.20232 15390070
15. Fernandez HH Friedman JH Fischman AJ Noto RB Lannon MC Is altropane SPECT more sensitive to fluoroDOPA PET for detecting early Parkinson's disease? Med Sci Monit 2001, 7:1339-1343 11687754
16. Huang WS Chiang YH Lin JC Chou YH Cheng CY Liu RS Crossover study of (99m)Tc-TRODAT-1 SPECT and (18)F-FDOPA PET in Parkinson's disease patients J Nucl Med 2003, 44:999-1005 12843212
17. Ishikawa T Dhawan V Kazumata K Chaly T Mandel F Neumeyer J Margouleff C Babchyck B Zanzi I Eidelberg D Comparative nigrostriatal dopaminergic imaging with iodine-123-beta CIT-FP/SPECT and fluorine-18-FDOPA/PET J Nucl Med 1996, 37:1760-1765 8917170
18. Schwarz J Antonini A Tatsch K Kirsch CM Oertel WH Leenders KL Comparison of 123I-IBZM SPECT and 11C-raclopride PET findings in patients with parkinsonism Nucl Med Commun 1994, 15:806-813 10.1097/ 00006231-199410000-00006 7838444
19. Booij J Tissingh G Winogrodzka A van Royen EA Imaging of the dopaminergic neurotransmission system using single-photon emission tomography and positron emission tomography in patients with parkinsonism Eur J Nucl Med 1999, 26:171-182 10.1007/s002590050374 9933352
20. Jankovic J Rajput AH McDermott MP Perl DP The evolution of diagnosis in early Parkinson disease. Parkinson Study Group Arch Neurol 2000, 57:369-372 10.1001/archneur.57.3.369 10714663
21. Walker Z Costa DC Walker RW Shaw K Gacinovic S Stevens T Livingston G Ince P McKeith IG Katona CL Differentiation of dementia with Lewy bodies from Alzheimer's disease using a dopaminergic presynaptic ligand J Neurol Neurosurg Psychiatry 2002, 73:134-140 10.1136/jnnp.73.2.134 12122169
22. Deville WL Bossuyt PM de Vet HC Bezemer PD Bouter LM Assendelft WJ Systematic reviews in practice. X. Searching, selecting and the methodological assessment of diagnostic evaluation research Ned Tijdschr Geneeskd 2002, 146:2281-2284 12497754
23. Assendelft WJ van Tulder MW Scholten RJ Bouter LM [The practice of systematic reviews. II. Searching and selection of studies] Ned Tijdschr Geneeskd 1999, 143:656-661 10321296
24. Deville WL Buntinx F Bouter LM Montori VM de Vet HC van der Windt DA Bezemer PD Conducting systematic reviews of diagnostic studies: Didactic guidelines BMC Med Res Methodol 2002, 2:9 117243 12097142 10.1186/ 1471-2288-2-9
25. Whiting PF Weswood ME Rutjes AW Reitsma JB Bossuyt PN Kleijnen J Evaluation of QUADAS, a tool for the quality assessment of diagnostic accuracy studies BMC Med Res Methodol 2006, 6:9 1421422 16519814 10.1186/ 1471-2288-6-9
26. Egger M Smith GD Altman DG Systematic reviews in health care BMJ Publishing Group, London 2005, 271
27. Higgins JP Thompson SG Deeks JJ Altman DG Measuring inconsistency in meta-analyses BMJ 2003, 327:557-560 192859 12958120 10.1136/ bmj.327.7414.557
28. Vlaar AMM Kessels AGH Nijs de T Winogrodzka A Mess WH Kroonenburgh MJPG Weber WEJ Additional value of SPECT imaging in comparance with clinical diagnosis in 248 patients with parkinsonism. Movement Disorders 2007, 22 Suppl 16: 233
29. Brucke T Asenbaum S Pirker W Djamshidian S Wenger S Wober C Muller C Podreka I Measurement of the dopaminergic degeneration in Parkinson's disease with [123I] beta-CIT and SPECT. Correlation with clinical findings and comparison with multiple system atrophy and progressive supranuclear palsy J Neural Transm Suppl 1997, 50:9-24 9120429
30. Lu CS Weng YH Chen MC Chen RS Tzen KY Wey SP Ting G Chang HC Yen TC 99mTc-TRODAT-1 imaging of multiple system atrophy J Nucl Med 2004, 45:49-55 14734673
31. Popperl G Radau P Linke R Hahn K Tatsch K Diagnostic performance of a 3-D automated quantification method of dopamine D2 receptor SPECT studies in the differential diagnosis of parkinsonism Nucl Med Commun 2005, 26:39-43 10.1097/00006231-200501000-00007 15604946
32. Swanson RL Newberg AB Acton PD Siderowf A Wintering N Alavi A Mozley PD Plossl K Udeshi M Hurtig H Differences in [99mTc]TRODAT-1 SPECT binding to dopamine transporters in patients with multiple system atrophy and Parkinson's disease Eur J Nucl Med Mol Imaging 2005, 32:302-307 10.1007/ s00259-004-1667-x 15791439
33. Asenbaum S Pirker W Angelberger P Bencsits G Pruckmayer M Brucke T [123I]beta-CIT and SPECT in essential tremor and Parkinson's disease J Neural Transm 1998, 105:1213-1228 10.1007/s007020050124 9928890
34. Schwarz J Tatsch K Gasser T Arnold G Pogarell O Kunig G Oertel WH 123I-IBZM binding compared with long-term clinical follow up in patients with de novo parkinsonism Mov Disord 1998, 13:16-19 10.1002/ mds.870130107 9452320
35. Schwarz J Tatsch K Arnold G Ott M Trenkwalder C Kirsch CM Oertel WH 123I-iodobenzamide-SPECT in 83 patients with de novo parkinsonism Neurology 1993, 43:S17-20 8264906
36. Booij J Speelman JD Horstink MW Wolters EC The clinical benefit of imaging striatal dopamine transporters with [123I]FP-CIT SPET in differentiating patients with presynaptic parkinsonism from those with other forms of parkinsonism Eur J Nucl Med 2001, 28:266-272 10.1007/ s002590000460 11315592
37. Schwarz J Tatsch K Gasser T Arnold G Oertel WH [123]IBZM binding predicts dopaminergic responsiveness in patients with parkinsonism and previous dopaminomimetic therapy Mov Disord 1997, 12:898-902 10.1002/ mds.870120610 9399212
38. Lokkegaard A Werdelin LM Friberg L Clinical impact of diagnostic SPET investigations with a dopamine re-uptake ligand Eur J Nucl Med Mol Imaging 2002, 29:1623-1629 10.1007/s00259-002-0938-7 12458397
39. Stoffers D Booij J Bosscher L Winogrodzka A Wolters EC Berendse HW Early-stage [(123)I]beta-CIT SPECT and long-term clinical follow-up in patients with an initial diagnosis of Parkinson's disease Eur J Nucl Med Mol Imaging 2005, 15682332
40. Haapaniemi TH Ahonen A Torniainen P Sotaniemi KA Myllyla VV [123I]beta-CIT SPECT demonstrates decreased brain dopamine and serotonin transporter levels in untreated parkinsonian patients Mov Disord 2001, 16:124-130 10.1002/1531-8257(200101) 16:1<124::AID-MDS1007>3.0.CO;2-R 11215571
41. Huang WS Lin SZ Lin JC Wey SP Ting G Liu RS Evaluation of early-stage Parkinson's disease with 99mTc-TRODAT-1 imaging J Nucl Med 2001, 42:1303-1308 11535717
42. Schwarz J Linke R Kerner M Mozley PD Trenkwalder C Gasser T Tatsch K Striatal dopamine transporter binding assessed by [I-123]IPT and single photon emission computed tomography in patients with early Parkinson's disease: Implications for a preclinical diagnosis Arch Neurol 2000, 57:205-208 10.1001/archneur.57.2.205 10681078
43. Van Laere K De Ceuninck L Dom R Van den Eynden J Vanbilloen H Cleynhens J Dupont P Bormans G Verbruggen A Mortelmans L Dopamine transporter SPECT using fast kinetic ligands: 123I-FP-beta-CIT versus 99mTc-TRODAT-1 Eur J Nucl Med Mol Imaging 2004, 31: 1119-1127 10.1007/s00259-004-1480-6 15064872
44. Muller T Farahati J Kuhn W Eising EG Przuntek H Reiners C Coenen HH [123I]beta-CIT SPECT visualizes dopamine transporter loss in de novo parkinsonian patients Eur Neurol 1998, 39:44-48 10.1159/000007896 9476723
45. Lee MS Kim YD Im JH Kim HJ Rinne JO Bhatia KP 123I-IPT brain SPECT study in essential tremor and Parkinson's disease Neurology 1999, 52:1422-1426 10227629
46. Plotkin M Amthauer H Klaffke S Kuhn A Ludemann L Arnold G Wernecke KD Kupsch A Felix R Venz S Combined (123)I-FP-CIT and (123)I-IBZM SPECT for the diagnosis of parkinsonian syndromes: Study on 72 patients J Neural Transm 2005, 112:677 692 10.1007/s00702-004-0208-x 15375677
47. Eerola J Tienari PJ Kaakkola S Nikkinen P Launes J How useful is [123I]beta-CIT SPECT in clinical practice? J Neurol Neurosurg Psychiatry 2005, 76:1211-1216 10.1136/jnnp.2004.045237 16107353
48. Benamer TS Patterson J Grosset DG Booij J de Bruin K van Royen E Speelman JD Horstink MH Sips HJ Dierckx RA Versijpt J Decoo D Van Der Linden C Hadley DM Doder M Lees AJ Costa DC Gacinovic S Oertel WH Pogarell O Hoeffken H Joseph K Tatsch K Schwarz J Ries V Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I]-FP-CIT SPECT imaging: The [123I]-FP-CIT study group Mov Disord 2000 15 503 510 10.1002/ 1531-8257(200005)15:3<503::AID-MDS1013>3.0.CO;2-V 10830416
49. Gerschlager W Bencsits G Pirker W Bloem BR Asenbaum S Prayer D Zijlmans JC Hoffmann M Brucke T [123I]beta-CIT SPECT distinguishes vascular parkinsonism from Parkinson's disease Mov Disord 2002, 17:518-523 10.1002/mds.10092 12112200
50. Kim YJ Ichise M Ballinger JR Vines D Erami SS Tatschida T Lang AE Combination of dopamine transporter and D2 receptor SPECT in the diagnostic evaluation of PD, MSA, and PSP Mov Disord 2002, 17:303-312 10.1002/mds.10042 11921116
51. Messa C Volonte MA Fazio F Zito F Carpinelli A d'Amico A Rizzo G Moresco RM Paulesu E Franceschi M Lucignani G Differential distribution of striatal [123I]beta-CIT in Parkinson's disease and progressive supranuclear palsy, evaluated with single-photon emission tomography Eur J Nucl Med 1998, 25:1270-1276 10.1007/s002590050295 9724376
52. Pirker W Djamshidian S Asenbaum S Gerschlager W Tribl G Hoffmann M Brucke T Progression of dopaminergic degeneration in Parkinson's disease and atypical parkinsonism: A longitudinal beta-CIT SPECT study Mov Disord 2002, 17:45-53 10.1002/mds.1265 11835438
53. Oyanagi C Katsumi Y Hanakawa T Hayashi T Thuy DD Hashikawa K Nagahama Y Fukuyama H Shibasaki H Comparison of striatal dopamine D2 receptors in Parkinson's disease and progressive supranuclear palsy patients using [123I] iodobenzofuran single-photon emission computed tomography J Neuroimaging 2002, 12:316-324 12380478
54. Oertel WH Schwarz J Tatsch K Arnold G Gasser T Kirsch CM IBZM-SPECT as predictor for dopamimetic responsiveness of patients with de novo parkinsonian syndrome Adv Neurol 1993, 60:519-524 8420182
55. Tatsch K Schwarz J Oertel WH Kirsch CM SPECT imaging of dopamine D2 receptors with 123I-IBZM: Initial experience in controls and patients with Parkinson's syndrome and Wilson's disease Nucl Med Commun 1991, 12:699-707 10.1097/00006231-199108000-00005 1838142
56. Buck A Westera G Sutter M Albani C Kung HF vonSchulthess GK Iodine-123-IBF SPECT evaluation of extrapyramidal diseases J Nucl Med 1995, 36:1196-1200 7790944
57. Seppi K Schocke MF Donnemiller E Esterhammer R Kremser C Scherfler C Diem A Jaschke W Wenning GK Poewe W Comparison of diffusion-weighted imaging and [123I]IBZM-SPECT for the differentiation of patients with the Parkinson variant of multiple system atrophy from those with Parkinson's disease Mov Disord 2004, 19:1438-1445 10.1002/mds.20229 15390073
58. Schelosky L Hierholzer J Wissel J Cordes M Poewe W Correlation of clinical response in apomorphine test with D2-receptor status as demonstrated by 123I IBZM-SPECT Mov Disord 1993, 8:453-458 10.1002/ mds.870080406 8232354
59. Pirker W Asenbaum S Wenger S Kornhuber J Angelberger P Deecke L Podreka I Brucke T Iodine-123-epidepride-SPECT: Studies in Parkinson's disease, multiple system atrophy and Huntington's disease J Nucl Med 1997, 38:1711-1717 9374338
60. van Royen E Verhoeff NF Speelman JD Wolters EC Kuiper MA Janssen AG Multiple system atrophy and progressive supranuclear palsy. Diminished striatal D2 dopamine receptor activity demonstrated by 123I-IBZM single photon emission computed tomography Arch Neurol 1993, 50:513-516 8489409
61. Pirker W Asenbaum S Bencsits G Prayer D Gerschlager W Deecke L Brucke T [123I]beta-CIT SPECT in multiple system atrophy, progressive supranuclear palsy, and corticobasal degeneration Mov Disord 2000, 15:1158-1167 10.1002/ 1531-8257(200011)15:6<1158::AID-MDS1015>3.0.CO;2-0 11104200
62. Seibyl JP Marek K Sheff K Zoghbi S Baldwin RM Charney DS van Dyck CH Innis RB Iodine-123-beta-CIT and iodine-123-FPCIT SPECT measurement of dopamine transporters in healthy subjects and Parkinson's patients J Nucl Med 1998, 39:1500-1508 9744331
63. Booij J Tissingh G Winogrodzka A Boer GJ Stoof JC Wolters EC van Royen EA Practical benefit of [123I]FP-CIT SPET in the demonstration of the dopaminergic deficit in Parkinson's disease Eur J Nucl Med 1997, 24:68-71 10.1007/BF01728311 9044880
64. Hierholzer J Cordes M Venz S Schelosky L Harisch C Richter W Keske U Hosten N Maurer J Poewe W Felix R Loss of dopamine-D2 receptor binding sites in Parkinsonian plus syndromes J Nucl Med 1998, 39:954-960 9627325
65. Pirker W Holler I Gerschlager W Asenbaum S Zettinig G Brucke T Measuring the rate of progression of Parkinson's disease over a 5-year period with beta-CIT SPECT Mov Disord 2003, 18:1266-1272 10.1002/mds.10531 14639666
66. Booij J Bergmans P Winogrodzka A Speelman JD Wolters EC Imaging of dopamine transporters with [123I]FP-CIT SPECT does not suggest a significant effect of age on the symptomatic threshold of disease in Parkinson's disease Synapse 2001, 39:101-108 10.1002/ 1098-2396(200102)39:2<101::AID-SYN1>3.0.CO;2-1 11180497
67. van Dyck CH Seibyl JP Malison RT Laruelle M Zoghbi SS Baldwin RM Innis RB Age-related decline in dopamine transporters: Analysis of striatal subregions, nonlinear effects, and hemispheric asymmetries Am J Geriatr Psychiatry 2002, 10:36-43 10.1176/appi.ajgp.10.1.36 11790633
68. Whone AL Watts RL Stoessl AJ Davis M Reske S Nahmias C Lang AE Rascol O Ribeiro MJ Remy P Poewe WH Hauser RA Brooks DJ Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study Ann Neurol 2003, 54:93-101 10.1002/ana.10609 12838524
69. Fahn S Parkinson disease, the effect of levodopa, and the ELLDOPA trial. Earlier vs Later L-DOPA Arch Neurol 1999, 56:529-535 10.1001/ archneur.56.5.529 10328247
70. Benamer HT Oertel WH Patterson J Hadley DM Pogarell O Hoffken H Gerstner A Grosset DG Prospective study of presynaptic dopaminergic imaging in patients with mild parkinsonism and tremor disorders: Part 1. Baseline and 3-month observations Mov Disord 2003, 18:977-984 10.1002/mds.10482 14502664
71. Lorberboym M Djaldetti R Melamed E Sadeh M Lampl Y 123I-FP-CIT SPECT imaging of dopamine transporters in patients with cerebrovascular disease and clinical diagnosis of vascular parkinsonism J Nucl Med 2004, 45:1688-1693 15471834
72. Schwarz J Kraft E Vogl T Arnold G Tatsch K Oertel WH Relative quantification of signal on T2-weighted images in the basal ganglia: limited value in differential diagnosis of patients with parkinsonism Neuroradiology 1999, 41:124-128 10.1007/s002340050716 10090605
73. Pizzolato G Cagnin A Rossato A Chierichetti F Fabbri M Dam M Ferlin G Battistin L Striatal dopamine D2 receptor alterations and response to L-DOPA in Parkinson's disease. A [123I]IBZM SPET study Adv Neurol 1996, 69:467-473 8615167
74. Schwarz J Tatsch K Arnold G Gasser T Trenkwalder C Kirsch CM Oertel WH 123I-iodobenzamide-SPECT predicts dopaminergic responsiveness in patients with de novo parkinsonism Neurology 1992, 42:556-561 1549216
75. Hierholzer J Cordes M Schelosky L Sander B Bock JC David I Horowski R Poewe W [The differential diagnosis of Parkinson diseases - 123I-IBZM-SPECT vs. the apomorphine test] Rofo 1993, 159:86-90 8334264
76. Knudsen GM Karlsborg M Thomsen G Krabbe K Regeur L Nygaard T Videbaek C Werdelin L Imaging of dopamine transporters and D2 receptors in patients with Parkinson's disease and multiple system atrophy Eur J Nucl Med Mol Imaging 2004, 31:1631-1638 10.1007/s00259-004-1578-x 15583914
77. Prunier C Tranquart F Cottier JP Giraudeau B Chalon S Guilloteau D De Toffol B Chossat F Autret A Besnard JC Baulieu JL Quantitative analysis of striatal dopamine D2 receptors with 123 I-iodolisuride SPECT in degenerative extrapyramidal diseases Nucl Med Commun 2001, 22:1207-1214 10.1097/00006231-200111000-00007 11606886
78. Schulz JB Klockgether T Petersen D Jauch M Muller-Schauenburg W Spieker S Voigt K Dichgans J Multiple system atrophy: Natural history, MRI morphology, and dopamine receptor imaging with 123IBZM-SPECT J Neurol Neurosurg Psychiatry 1994, 57:1047-1056 8089667
79. Berding G Gratz KF Kolbe H Meyer GJ Dengler R Knoop BO Hundeshagen H 123I-IBZM SPECT: Reconstruction methodology and results in parkinsonism and dystonia Nuklearmedizin 1994, 33:194-199 7997377
80. Bettin S Kampfer I Seese A Schafer A Reuter M Lossner J Dietrich J Wagner A Knapp WH [Striatal uptake of I-123-beta-CIT and I-123-IBZM in patients with extrapyramidal symptoms] Nuklearmedizin 1997, 36:167-172 9380528
81. Scherfler C Seppi K Donnemiller E Goebel G Brenneis C Virgolini I Wenning GK Poewe W Voxel-wise analysis of [123I] beta-CIT SPECT differentiates the Parkinson variant of multiple system atrophy from idiopathic Parkinson's disease Brain 2005
82. Staffen W Mair A Unterrainer J Trinka E Ladurner G Measuring the progression of idiopathic Parkinson's disease with [123I] beta-CIT SPECT J Neural Transm 2000, 107:543-552 10.1007/s007020070077 11072750
83. Thobois S Jahanshahi M Pinto S Frackowiak R Limousin-Dowsey P PET and SPECT functional imaging studies in Parkinsonian syndromes: From the lesion to its consequences Neuroimage 2004, 23:1-16 10.1016/ j.neuroimage.2004.04.039 15325346
84. Parkinson Study Group A multicenter assessment of dopamine transporter imaging with DOPASCAN/SPECT in parkinsonism. Neurology 2000, 55:1540-1547 11094111